Table 1.
Compound | Cell Lines | |||
---|---|---|---|---|
CCD18 Co | HT29 | MCF-10A | MCF-7 | |
(−)-Glaucarubolone | NI | NI | NI | NI |
(−)-Holacanthone | <5 | 9.91 ± 0.52 | 0.3 ± 1.25 | 11.031 ± 1.13 |
(−)-Glaucarubolone glucoside |
40.14 ± 3.41 | NI | NI | 8.65 ± 1.11 |
Scopoletin | NI | 19.28 ± 0.348 | NI | NI |
Tamoxifen | ND | ND | 38.9 ± 1.19 | 17.28 ± 0.06 |
5-Fluorouracil | 55.51 ± 3.71 | 23.50 ± 1.12 | NI | 78.6 ± 1.73 |
Doxorubicin | ND | ND | 30.2 ± 1.29 | NI |
Cells were exposed to the isolates or anticancer agents (1 nM-100 μM) for 24 h before cytotoxicity analysis using the MTS or the Alamar Blue™ assay. IC50 represents the concentration needed to inhibit the growth of cancer cells by 50%. These values (μM) were obtained from the interaction of isolates with various cancer and normal cell lines along with positive controls (standard of care agents Tamoxifen, Fluorouracil and Doxorubicin), as outlined in Materials and Methods. Results are represented as the mean of at least three independent experiments ±SEM. Key: NI: No inhibition (<10% inhibition at 60 μM), ND: Not determined.